

Korea's LOTTE Biologics inks US-based manufacturing agreement with Alvotech to increase global supply

October 9, 2026 | News

Collaboration covers multiple biosimilar products to be manufactured at LOTTE Biologics' Syracuse facility in New York



South Korea-based LOTTE Biologics, a contract development and manufacturing (CDMO) organisation, and Alvotech, a global biotechnology company specialising in the development and manufacture of biosimilar medicines for patients worldwide, have announced a long-term strategic manufacturing partnership.

Under the agreement, LOTTE Biologics will manufacture drug substance for multiple antibody biosimilar products at its Syracuse facility in New York for global supply, with the potential to further expand the collaboration over time.

The Syracuse facility has 40,000 liters of bioreactor capacity for biologics manufacturing, supported by on-site process development and quality control capabilities. The site has an established track record in commercial biologics manufacturing and recently completed an unannounced FDA inspection with zero observations, further demonstrating its strong quality and regulatory capabilities.

The agreement positions LOTTE Biologics as a partner to expand Alvotech's US-based manufacturing footprint while strengthening its global supply network. The additional capacity complements Alvotech's existing manufacturing partnerships and its in-house development and manufacturing capabilities, supporting its expanding portfolio and providing greater flexibility to meet demand across international markets.